BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test
December 23, 2015 07:50 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification...
License and Distribution Agreement Amended
November 30, 2015 07:40 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3® Test, today announced an amendment to its license and distribution...
BG Medicine Reports Third Quarter 2015 Financial Results
November 17, 2015 07:50 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three and nine months ended...
BG Medicine Announces Business Update Conference Call Information
November 11, 2015 16:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17,...
BG Medicine to Begin Trading on the OTCQB
September 15, 2015 13:27 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today announced that on September 14, 2015, the Company was...
BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results
August 14, 2015 16:43 ET
|
BG Medicine, Inc.
Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S.
Operating Cash Burn for Second Quarter of 2015 Reduced by 68% From Second Quarter of 2014
-- Company to Host...
BG Medicine Prices Underwritten Public Offering
August 13, 2015 08:35 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced the pricing of an underwritten public offering of its...
BG Medicine Announces Proposed Underwritten Public Offering
August 12, 2015 16:28 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell equity securities...
BG Medicine Welcomes U.S. Market Introduction of Automated Galectin-3 Test at the 2015 American Association for Clinical Chemistry Annual Meeting
July 27, 2015 08:00 ET
|
BG Medicine, Inc.
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical...
BG Medicine Announces Payoff of Secured Term Loan
July 15, 2015 07:00 ET
|
BG Medicine, Inc.
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that it has paid off its secured term loan facility...